Dr. Kelly Roszko is an Adult Endocrinologist at the National Institutes of Health. Her interest in bone and mineral metabolism began during her M.D., Ph.D. training at the University of Connecticut. She initially studied hyperparathyroidism and completed her PhD dissertation under the mentorship of Dr. Andrew Arnold, M.D. She then completed internship and residency in Internal Medicine as well as fellowship in Endocrinology at the Massachusetts General Hospital/Harvard Medical School in Boston. There, with the mentorship of Dr. Michael Mannstadt, she focused on Autosomal Dominant Hypocalcemia Type 2 (ADH2), creating a mouse model of the disease and testing treatments. She is now working in the Skeletal Disorders and Mineral Homeostasis Section, led by Dr. Michael Collins, at the National Institute of Dental and Craniofacial Research, National Institutes of Health. She has published numerous manuscripts including those focused on Autosomal Dominant Hypocalcemia Type 1 and 2. As a physician-scientist, she is pursuing both projects in the basic science of calcium and phosphate homeostasis, and in translational medicine with the goal of bringing new treatments to patients with hypoparathyroidism and other rare diseases of mineral metabolism.